Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

PURPOSE OF REVIEW: Rituximab-based chemoimmunotherapy has resulted in a marked improvement in the survival of diffuse large B cell lymphoma (DLBCL). We reflect upon the history front-line (1L) therapy and highlight advances in management. RECENT FINDINGS: Since the introduction of R-CHOP, the majori...

Descripción completa

Detalles Bibliográficos
Autores principales: Kesavan, Murali, Eyre, Toby A., Collins, Graham P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647877/
https://www.ncbi.nlm.nih.gov/pubmed/31254155
http://dx.doi.org/10.1007/s11899-019-00518-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647877/
https://www.ncbi.nlm.nih.gov/pubmed/31254155
http://dx.doi.org/10.1007/s11899-019-00518-8

Ejemplares similares